Research Scope: Microplastic Dose-Response
ALETHEIA Safety Intelligence — Quantifying hazard thresholds and human exposure margins for microplastic compounds
1 Research Question
The ALETHEIA database contains 11 microplastic compounds (PE, PP, PS, PET, nylon, acrylic, polyester microfibers, tire wear particles, etc.) all flagged with no_substitute_reason: "degradation_product". But the database currently lacks dose-response data to contextualize risk. At what exposure levels do microplastics cause measurable harm? Is the current human exposure level concerning, or orders of magnitude below effect thresholds?
This research scope defines a systematic investigation into the toxicological significance of microplastic exposure across particle size ranges, polymer types, and human exposure routes. The goal is to establish quantitative dose-response relationships, estimate human exposure margins of safety, and inform database updates with evidence-based risk characterization.
2 Scope & Compounds
This research encompasses 11 microplastic compounds currently in the ALETHEIA database:
| Compound | Polymer Type | Primary Source | Size Range | Human Exposure Route |
|---|---|---|---|---|
| PE microplastics | Polyethylene | Packaging degradation | 1–5000 μm | Ingestion, inhalation |
| PP microplastics | Polypropylene | Food containers | 1–5000 μm | Ingestion |
| PS microplastics | Polystyrene | Foam packaging | 0.1–5000 μm | Ingestion, inhalation |
| PET microfibers | Polyester | Textile washing | 5–5000 μm | Ingestion (water), inhalation |
| Nylon microfibers | Polyamide | Textile washing | 10–3000 μm | Ingestion, inhalation |
| Tire wear particles | SBR/NR blend | Road abrasion | 5–350 μm | Inhalation, ingestion (water) |
| Acrylic microfibers | PMMA | Textile washing | 10–2000 μm | Ingestion, inhalation |
| Plus 4 additional microplastic entries | ||||
All 11 compounds are currently flagged as degradation products with no readily available substitutes. This research will systematically evaluate their toxicological potential across multiple endpoints and exposure scenarios.
3 Evidence Framework
The research leverages three complementary evidence streams:
In-vitro Toxicology
Cell line studies (Caco-2 gut epithelium, A549 lung alveolar cells, THP-1 macrophages) examining cytotoxicity, oxidative stress, and inflammatory response at various concentrations. Key variable: particle size — nanoplastics (<1 μm) readily cross cell membranes and trigger subcellular effects; microplastics (>10 μm) trigger epithelial barrier disruption and innate immune pathways. Range of tested doses: 1 μg/mL to 100 μg/mL.
In-vivo Animal Studies
Mouse and rat gavage (oral) and inhalation exposure studies at 0.1–100 mg/kg/day showing gut inflammation, microbiome disruption, barrier dysfunction, and systemic distribution to liver, spleen, and kidney. Critical gap: most published studies use pristine spherical polystyrene beads; environmentally weathered, irregular fragments—the actual exposure form—remain understudied.
Human Epidemiology & Biomonitoring
Schwabl et al. (2019) detecting microplastics in human stool; Leslie et al. (2022) detecting microplastics in human blood; Ragusa et al. (2021) detecting microplastics in human placental tissue. Reverse-engineering human exposure doses from biomonitoring data coupled with pharmacokinetic modeling enables margin-of-safety estimation.
4 Methodology
Integrated Hazard & Exposure Assessment Approach
Systematic Literature Review
Comprehensive PubMed and Web of Science search for microplastic toxicity studies (2018–2026), filtered by human-relevant endpoints (inflammation markers, barrier function, organ distribution, systemic effects). Data extraction standardized using a structured form capturing: polymer type, particle size, dose range, endpoint, effect levels (NOAEL, LOAEL, EC₅₀), and study quality metrics.
Dose-Response Modeling
Benchmark Dose (BMD) analysis applied to dose-response datasets from in-vitro and in-vivo studies. Point of departure (POD) derived using standard BMD software (e.g., EPA BMDS). Extrapolation to human equivalent doses using allometric scaling (body weight and metabolic rate adjustments).
Human Exposure Assessment
Synthesis of microplastic intake estimates from Cox et al. (2019)—approximately 74,000–121,000 particles/year via combined ingestion and inhalation routes. Comparison of estimated human intake to derived effect thresholds to establish preliminary margins of exposure.
Physiologically-Based Pharmacokinetic (PBPK) Simulation
Compartmental modeling of nano- and microplastic absorption, distribution, and fate across gut, blood, and target organs (liver, spleen, kidney, reproductive tissues). Partition coefficients and absorption rates derived from particle size-dependent translocation literature.
Margin of Exposure (MOE) Calculation
Quantitative MOE = [POD or effect threshold] / [estimated human exposure]. MOE > 1000 typically indicates low hazard concern; MOE < 100 suggests need for risk reduction measures. Size-stratified and polymer-stratified MOEs generated.
5 Expected Outcomes
Primary Deliverables
- Quantitative dose-response curves for key microplastic types (PE, PP, PS, PET) and endpoints (cytotoxicity, inflammation, translocation)
- Human exposure margin of safety estimate — are current exposures at 0.1%, 1%, or 10% of effect levels?
- Size-dependent risk classification: nanoplastics (<100 nm) vs. microplastics (1–5000 μm) with distinct hazard profiles
- Database update: All 11 microplastic compounds annotated with
dose_response_summary,exposure_margin, andhazard_classificationfields - Evidence gap analysis identifying priority areas for future research (e.g., weathered fragments, chronic low-dose studies, reproductive endpoints)
6 Timeline & Phases
Systematic search across PubMed, Web of Science, and gray literature; screening ~80–150 papers; standardized extraction of dose-response data and study quality metrics.
Fit dose-response curves; derive Points of Departure (NOAEL, BMD₁₀, EC₅₀) for primary endpoints; quality-weight studies; perform sensitivity analyses.
Integrate Cox et al. intake estimates; refine intake by exposure route (ingestion vs. inhalation); uncertainty analysis (low, central, high estimates).
Build and parameterize compartmental models; simulate distribution kinetics; compute size-stratified MOE values; generate MOE uncertainty ranges.
Implement new fields across all 11 microplastic entries; write technical summary; prepare for publication in ALETHEIA platform.
Total Duration: ~9 weeks (accounting for review cycles and iterative refinement)